[Bronchial asthma. Clinical evolution with hyposensitization (author's transl)]

Area of Science:

• Pediatrics
• Allergology
• Immunology

Background:

• Bronchial asthma is a common chronic respiratory condition in children.
• Hyposensitization therapy (allergen immunotherapy) is a treatment option for allergic diseases.
• Delayed diagnosis and treatment initiation are common challenges in pediatric asthma management.

Purpose of the Study:

• To evaluate the clinical evolution of bronchial asthma in children treated with hyposensitization therapy.
• To analyze factors influencing treatment outcomes, including sex, age of onset, and treatment duration.
• To assess the time course of clinical improvement following hyposensitization therapy.

Main Methods:

• A cohort study of 94 children with diagnosed bronchial asthma receiving hyposensitization therapy for 18 months and 43 children for 24 months.
• Analysis of patient demographics: sex, etiology, age of illness onset, and age at treatment initiation.
• Clinical assessment of asthma symptom evolution and control during and after therapy.

Main Results:

• Hyposensitization therapy demonstrated statistically significant clinical improvement in children with bronchial asthma.
• The majority of patients achieved good illness control with symptom resolution.
• Treatment effectiveness showed a correlation with the duration of illness, but not with sex or age of onset.

Conclusions:

• Hyposensitization therapy is an effective treatment for pediatric bronchial asthma, leading to significant symptom reduction and disease control.
• The benefits of hyposensitization therapy may manifest over time, with noticeable clinical improvement observed up to 24 months post-treatment initiation.
• While not dependent on sex or age of onset, the duration of illness may influence treatment outcomes.